STM-01

About Secretome Therapeutics

Secretome Therapeutics is a private, clinical-stage biotech founded in 2018 and headquartered in Cambridge, USA, with additional offices in Baltimore, Chicago, and Plano. The company's core innovation is a scalable platform using neonatal cardiac progenitor cells (nCPCs), which offer advantages in potency, manufacturing consistency, and ethical sourcing compared to adult-derived stem cells. It has two active Phase 1 clinical programs targeting DCM and HFpEF, positioning it in the competitive but high-need field of cell therapies for heart failure. The company is currently pre-revenue and focused on clinical development.

About Secretome Therapeutics

Secretome Therapeutics is a private, clinical-stage biotech founded in 2018 and headquartered in Cambridge, USA, with additional offices in Baltimore, Chicago, and Plano. The company's core innovation is a scalable platform using neonatal cardiac progenitor cells (nCPCs), which offer advantages in potency, manufacturing consistency, and ethical sourcing compared to adult-derived stem cells. It has two active Phase 1 clinical programs targeting DCM and HFpEF, positioning it in the competitive but high-need field of cell therapies for heart failure. The company is currently pre-revenue and focused on clinical development.

Therapeutic Areas